A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
Completed · Phase 2
Conditions studied: Metastatic Pancreatic Cancer, Nonresectable Pancreatic Cancer
In brief
To evaluate the safety and effectiveness of CG8020 and CG2505.
Key facts
- Study ID
- NCT00245362
- Run by
- Cell Genesys
- People needed
- 50
- Starts
- 2002-06-01
- Expected to finish
- 2004-06-01
- Last updated by the study team
- 2005-10-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologic or cytologic diagnosis of nonresectable or metastatic pancreatic adenocarcinoma
- Chemotherapy naïve or chemotherapy experienced pancreatic cancer
You may not qualify if…
- Prior cancer vaccines or gene therapy
- History of clinically significant autoimmune disease (eg, systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis)
- History of another malignancy in the past five years, except adequately treated non-melanomatous skin cancer or superficial bladder cancer or carcinoma-in-situ of the cervix, unless approved by the Medical Monitor
Where it is running
- Johns Hopkins University School of Medicine — Baltimore, Maryland, United States
- US Oncology — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.